Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition

BH3-mimetics are a new class of anti-cancer drugs that inhibit anti-apoptotic Bcl-2 proteins. In doing so, BH3-mimetics sensitise to cell death. Venetoclax is a potent, BCL-2 selective BH3-mimetic that is clinically approved for use in chronic lymphocytic leukaemia. Venetoclax has also been shown to...

Descripción completa

Detalles Bibliográficos
Autores principales: Roca-Portoles, Alba, Rodriguez-Blanco, Giovanny, Sumpton, David, Cloix, Catherine, Mullin, Margaret, Mackay, Gillian M., O’Neill, Katelyn, Lemgruber, Leandro, Luo, Xu, Tait, Stephen W. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426836/
https://www.ncbi.nlm.nih.gov/pubmed/32792521
http://dx.doi.org/10.1038/s41419-020-02867-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426836/
https://www.ncbi.nlm.nih.gov/pubmed/32792521
http://dx.doi.org/10.1038/s41419-020-02867-2

Ejemplares similares